Latest ArticlesTo analyze the effect of Jianpi Qinghua decoction on islet cell differentiation in obese mice induced by high fat diet.
Six-week-old male C57BL/6 mice were randomly divided into normal group and high fat diet group after adaptive feeding for 1 week. After successful modeling, the high-fat group was randomly divided into model group and Jianpi Qinghua decoction group. After 6 weeks of intervention, body mass, fasting blood glucose (FBG), fasting insulin (FINS), glucose tolerance and lipid metabolism indexes of mice in each group were measured. Hematoxylineosin staining was used to observe the morphology and structure of pancreatic tissue. Immunofluorescence co-staining was used to observe the quantity and distribution of α cells, β cells and progenitor cell marker neurogenin (Ngn)3.
At the 5th week, the body weight of the high fat group was significantly increased compared with the normal group (P<0.01), and the body weight of the Jianpi Qinghua decoction group was decreased compared with the model group (P<0.05). After 30 min of glucose injection, blood glucose of the model group was significantly higher than that of the normal group (P<0.01). After 30, 60, 90 and 120 min of glucose injection, the blood glucose level and area under the curve of Jianpi Qinghua decoction group were significantly decreased compared with model group (P<0.01). FINS levels in Jianpi Qinghua decoction group were significantly decreased (P<0.01). The levels of serum cholesterol and triacylglycerol in Jianpi Qinghua decoction group were lower than those in model group (P<0.01). Fluorescence co-staining showed that β-cell and α-cell in Jianpi Qinghua decoction group increased significantly, and Ngn3, a marker of β-cell dedifferentiation and progenitor cell, was significantly decreased.
Jianpi Qinghua decoction can effectively reduce the levels of blood glucose, blood lipid and insulin in obese mice induced by high fat diet, which may be related to reversing the dedifferentiation of pancreatic β cells.
To investigate the effect of flurbiprofen axetil on hypoxia/reoxygenation (H/R)-induced neuronal injury and its regulatory mechanism.
Neuronal injury model was induced by H/R. Cell survival rate was detected by cell counting kit-8. The apoptosis rate was detected by flow cytometry. The neuronal injury was observed by transmission electron microscopy. The expression of oxidative stress and inflammatory factors were detected by enzyme linked immunosorbent assay. The protein level of the pathway was detected by western blotting (WB).
Compared with the control group, the neurons in the H/R group were severely damaged, the neuronal survival rate [(40.51±4.03)% vs 100%] was reduced, the apoptosis rate [(66.48±6.83)% vs (1.03±0.18)%] and the oxidative stress and inflammatory response were increased, and the Akt/GSK-3β/Nrf2/HO-1 signaling pathway was activated (P<0.01). Flurbiprofen axetil can alleviate H/R-induced neuronal injury, elevated neuronal survival rate [(73.36±7.08)% vs (40.51±4.03)%], reduce cell apoptosis rate [(32.27±3.45)% vs (66.48±6.83)%], and inhibit oxidative stress, inflammatory response and the Akt/GSK-3β/Nrf2/HO-1 signaling pathway (P<0.01).
Flurbiprofen axetil may protect neurons from H/R-induced injury by promoting the activation of oxidative stress pathway.
To explore the therapeutic effect of balancing cupping combined with ear-tip bloodletting on pruritus of chronic kidney disease.
A total of 60 patients with stage 4 to 5 chronic kidney disease with pruritus who treated in the department of nephrology, Jiangsu Hospital of Traditional Chinese Medicine from October 2020 to April 2021 were selected. The patients were randomly divided into control group and experimental group, and 30 cases each group. The control group was treated with conventional treatment and nursing, and the experimental group was treated with balanced cupping combined with ear-tip bloodletting on the basis of the control group. Evaluate the intervention effect with the uremic skin itching score as the primary efficacy indicator and the quality of life scale score as the secondary efficacy indicator.
After treatment, the total score and various scores of uremic skin itching score in both groups decreased compared to before treatment (P<0.05), and the improvement of symptoms and signs, sleep, and total score in the experimental group was better than that in the control group (P<0.05). The total score and various scores of life scales in both groups decreased compared to before treatment (P<0.05), and the improvement degree of the experimental group is better than that of the control group (P<0.05). No adverse reactions were observed during the treatment period.
On the basis of routine treatment and skin nursing, the combination of balanced cupping and ear-tip bloodletting can improve the pruritus of chronic kidney disease and the quality of life of patients.
To rapidly evaluate the efficacy, safety and economy of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV), so as to provide evidence-based support for clinical drug use.
By retrieving several major Chinese and English database, HTA reports, systematic reviews/meta-analysis and pharmacoeconomic studies about palonosetron in the prevention of CINV were included. The quality evaluation and summary analysis of the included literature were performed.
A total of 17 literatures were included, involving 7 systematic reviews/meta-analysis and 10 pharmacoeconomic studies. In terms of effectiveness, palonosetron had obvious advantages in the complete control rate of CINV in acute phases, delay phases and overall phases compared with the first generation 5-hydroxytryptamine 3 receptor antagonist (5-HT3RA). In terms of safety, there was no statistical significance in the incidence of common adverse reaction between palonosetron and other 5-HT3RA (P>0.05). Pharmacoeconomic studies showed that the efficacy of palonosetron was higher than other 5-HT3RA, but the cost was higher as well. It was necessary to compare the threshold of willingness to pay to determine its economy.
Palonosetron has good efficacy and safety in preventing CINV, but the economy needs to be further verified.
To analyze the effects of Wenshen Jiedu decoction combined with compound α-ketoacid tablets on renal deficiency and blood stasis type diabetic nephropathy (DN), and its effects on serum hepatocyte growth factor (HGF), thrombin-activatable fibrinolysis inhibitor (TAFI) and interleukin (IL)-21 levels.
A total of 160 DN patients with renal deficiency and blood stasis admitted to the department of nephrology, Shangqiu hospital of traditional Chinese medicine (TCM) from January 2020 to January 2022 were selected and divided into control group and experimental group according to random number table method, with 80 cases in each group. Both groups were given captopril orally under the precondition of controlling blood glucose, the control group was given compound α-ketoacid tablets, and the experimental group was given Wenshen Jiedu decoction on the basis of the control group. After 3 months continuous treatment, the efficacy and the occurrence of adverse reactions were evaluated, and the TCM syndrome scores, fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hPG), glycosylated hemoglobin (HbA1c), 24-hour urinary protein excretion rate (24hUAER), serum creatinine (Scr), esti mated glomerular filtration rate (eGFR), serum HGF, TAFI and IL-21 before and after treatment were analyzed in both groups.
The total effective rate of experimental group was higher than that of control group (91.25% vs 80.00%, P<0.05). The scores of TCM syndromes in experimental group were lower than those in control group after 1 month and 3 months of treatment (P<0.05). The levels of FBG, 2hPG, HbA1c, 24hUAER, Scr, eGFR and serum HGF, TAFI and IL-21 in both groups were significantly improved, and the improvements in experimental group were more significant (P<0.05).
Wenshen Jiedu decoction combined with compound α-ketoacid tablet can effectively regulate serum HGF, TAFI and IL-21 levels, control blood glucose and improve renal function in DN patients with renal deficiency and blood stasis, with good efficacy and safety.
To explore the clinical effects of levosimendan on children requiring veno-arterial extracorporeal membrane oxygenation (VA-ECMO) after cardiac surgery.
Children who underwent cardiac surgery in the department of pediatrics, Dazu district people's hospital of Chongqing from January 2016 to October 2021, and needed VA-ECMO support after surgery and tried to quit ECMO were selected and were divided into levosimendan group (n=43) and control group (n=52). Dual robust estimation method was used to balance study covariates, including baseline characteristics, vasoactive inotropic score (VIS), the risk adjustment in congenital heart surgery-1 method (RACHS-1), and further adjustment of the final model according to the duration of ECMO. Kaplan-Meier method was used to estimate the survival rate 30 days after intubation, and log-rank test was performed.
The duration of ECMO operation in levosimendan group was longer than that in control group, and the difference was statistically significant (P<0.001). The offline failure rates of levosimendan group and control group were 4.65% and 21.15%, respectively, and the difference was statistically significant (P<0.05). After regression adjustment for ECMO duration, the levosimendan group had a lower risk of offline failure [adjusted relative risk (95% confidence interval): 0.20 (0.07 to 0.57)] and a lower risk of hospitalization death [adjusted relative risk (95% confidence interval): 0.45 (0.26 to 0.76)] than the control group. Kaplan-Meier survival curve showed that the 30-day survival rate of levosimendan group was higher than that of control group (88.37% vs 65.38%, P<0.001).
Levosimendan therapy can reduce the risk of off-line failure and in-hospital mortality in children requiring VA-ECMO after cardiac surgery.
To evaluate the efficacy and safety of nafamostat mesylate as an anticoagulant regimen in maintenance hemodialysis (MHD).
30 patients with high risk of bleeding in the department of nephrology, Shanghai fourth people's hospital were selected as the observation group, receiving the anticoagulant regimen of nafamostat mesylate, and 30 patients with MHD were selected as the control group, receiving the anticoagulant regimen of ordinary heparin. Blood routine, liver and kidney function, blood lipid status, compression hemostasis time of arterial puncture point, and activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) in vitro and in vivo were observed before and after MHD in the two groups.
The levels of blood urea and creatinine after MHD in both groups were significantly lower than those before dialysis (P<0.05). In the observation group, APTT index in vivo was not significantly prolonged after HD, but APTT index in vitro was significantly prolonged (P<0.05). In the control group, APTT and TT index in vivo and in vitro were significantly prolonged (P<0.05). In terms of mechanical coagulation observation, the compression hemostasis time of MHD artery puncture in the observation group was significantly shorter than that in the control group (P<0.05).
Nafamostat mesylate is a safe and effective anticoagulant regimen for MHD patients at high risk of bleeding.
To evaluate the optimization effects of ciprofol combined with alfentanil for painless gastroscopy in patients with diabetes mellitus (DM).
A total of 88 DM patients who underwent painless gastroscopy in the first affiliated hospital of Zhengzhou university were enrolled and randomly divided into ciprofol combined with alfentanil group (group C) and propofol combined with alfentanil group (group P) by random number table method, with 44 cases in each group. Group C received intravenous injection of alfentanil and ciprofol, and group P received intravenous injection of alfentanil and propofol. The success rate of sedation, duration of sedation onset, time to recovery, time to discharge, incidence of adverse events, and satisfaction of anesthesiologists, endoscopists, and patients were recorded.
The incidence of bradycardia, hypotension, respiratory depression and injection pain in group P was lower than that in group C (22.73% vs 9.09%, 56.89% vs 20.45%, 38.64% vs 6.82%, 59.09% vs 4.55%, P<0.05). Compared with group C, the anesthesiologists and patients satisfaction in group P increased [(6.82±0.80) vs (8.03±0.60), (8.82±0.70) vs (9.44±1.20), (P<0.05)].
Compared with conventional anesthesia, ciprofol combined with alfentanil can optimize the safety and effectiveness of painless gastroscopy in DM patients.
To explore the clinical effects of Banxia Xiexin decoction combined with zopiclone tablets in the treatment of perimenopausal insomnia patients with phlegm-fire disturbing heart syndrome.
A total of 150 perimenopausal insomnia patients with phlegm-fire disturbing heart syndrome in our hospital were selected and divided into observation group and control group by random number table method, 75 cases in each group. The control group was treated with zopiclone tablets, and the observation group was treated with Banxia Xiexin decoction combined with zopiclone tablets. After treatment, the total effective rate of the two groups was compared. The score of Pittsburgh sleep quality index scale and traditional Chinese medicine syndrome score were observed. The laboratory examination indicators and adverse reactions before and after treatment were compared between the two groups.
After 4 weeks of treatment, the total effective rate of the observation group was 95.89% (70/73) higher than that of the control group 81.94% (59/72, χ2=7.181, P=0.007). After 2 and 4 weeks of treatment, the Pittsburgh sleep quality index score, traditional Chinese medicine syndrome score, serum follicle stimulant hormone, malondialdehyde, peptide and α-amylase in observation group were lower than those in control group, and glutathione peroxidase was higher than that in control group (P<0.05). There was no significant difference in adverse reactions between the two groups (χ2=0.280, P=0.597).
Banxia Xiexin decoction combined with zopiclonone tablet has good efficacy and safety in the treatment of perimenopausal insomnia patients with phlegm fire disturbing heart syndrome. It can effectively regulate the activity of sex hormone and sympathetic nerve, reduce the level of oxidative stress, improve sleep quality.
To evaluate the efficacy and safety of third-line treatment of duvarizumab combined with apatinib in the treatment of unresectable advanced colorectal cancer (CRC).
Sixty-six unresectable advanced CRC patients who received combination therapy (combination group, n=30) or apatinib monotherapy (monotherapy group, n=36) as third-line treatment were included. All patients were treated until intolerance or disease progression. The overall treatment response, objective response rate, disease control rate and incidence of adverse events were compared between the two groups.
The overall response in the combination group was higher than that of the monotherapy group (P=0.025). The rates of complete response, partial response, stable disease, and disease progression in the combination group were 0, 26.67%, 50.00%, and 23.33%, respectively. Meanwhile, those in the monotherapy group were 0, 8.33%, 47.23%, and 44.44%, respectively. The objective response rate in the combination group was higher than that in the monotherapy group (26.67% vs 8.33%, P=0.047), but the difference was not statistically significant in disease control rate between the two groups (76.67% vs 55.56%, P=0.073). The progression-free survival (median: 8.60 months vs 4.50 months, P=0.012) and overall survival (median: 15.70 months vs 8.10 months, P=0.009) of combination group were superior to those of the monotherapy group. The incidence of adverse events in the combination group was similar to that in the monotherapy group (P>0.05). Most adverse events in the combination group were grade 1 - 2, and only 7 patients (23.33%) had grade 3 - 4 adverse events.
Third-line treatment of duvaliuzumab combined with apatinib could improve the response rate and prolong survival in patients with unresectable advanced CRC with an acceptable safety profile.